FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Dillione Janet 2. Issuer Name and Ticker or Trading Symbol CorMedix Inc. [ CRMD ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O CORMEDIX INC., 400 CONNELL DRIVE, SUITE 5000
3. Date of Earliest Transaction (MM/DD/YYYY)
5/15/2020
(Street)
BERKELEY HEIGHTS, NJ 07922
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                 53473.0000  D 
 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock  $0.0000  5/15/2020    A     5253.0000       (1)  (1) Common Stock  5253.0000  $0.0000  5253.0000  D 
 
Stock Option (Right to Buy Common Stock)  $5.6300                   (2) 2/25/2030  Common Stock  15000.0000    15000.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  1706.0000    1706.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  2099.0000    2099.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  945.0000    945.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  1126.0000    1126.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  843.0000    843.0000  D 
 
Stock Option (Right to Buy Common Stock)  $8.3000                   (3) 1/10/2029  Common Stock  15000.0000    15000.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  1328.0000    1328.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  2728.0000    2728.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  7500.0000    7500.0000  D 
 
Stock Option (Right to Buy Common Stock)  $2.8500                   (4) 2/16/2028  Common Stock  8000.0000    8000.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  2679.0000    2679.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  3125.0000    3125.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  4167.0000    4167.0000  D 
 
Stock Option (Right to Buy Common Stock)  $11.2000                   (5) 2/21/2027  Common Stock  8000.0000    8000.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  695.0000    695.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  829.0000    829.0000  D 
 
Stock Option (Right to Buy Common Stock)  $15.1500                   (6) 8/11/2025  Common Stock  10000.0000    10000.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  283.0000    283.0000  D 
 
Stock Option (Right to Buy Common Stock)  $9.5500                   (7) 2/21/2026  Common Stock  19000.0000    19000.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  767.0000    767.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  554.0000    554.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  867.0000    867.0000  D 
 
Phantom Stock  $0.0000                   (1)  (1) Common Stock  3062.0000    3062.0000  D 
 

Explanation of Responses:
(1)  Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director.
(2)  These options were granted on 02/25/2020. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board.
(3)  These options were granted on 01/10/2019. These options are fully vested.
(4)  These options were granted on 02/16/2018. These options are fully vested.
(5)  These options were granted on 02/21/2017. These options are fully vested.
(6)  These options were granted on 08/12/2015. These options are fully vested.
(7)  These options were granted on 02/21/2016. These options are fully vested.

Remarks:
The Issuer effected a 1-for-5 reverse stock split of its common stock on March 26, 2019. All share and per share exercise price amounts shown in this Form 4 have been adjusted to reflect the reverse stock split.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Dillione Janet
C/O CORMEDIX INC.
400 CONNELL DRIVE, SUITE 5000
BERKELEY HEIGHTS, NJ 07922
X



Signatures
/s/ Janet Dillione 5/18/2020
**Signature of Reporting Person Date
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more CorMedix Charts.
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more CorMedix Charts.